Effect of combination chemotherapy with cisplatin and cyclophosphamide on human immunodeficiency virus type-1 surrogate markers in a patient with advanced epithelial ovarian cancer.
This is the first report to evaluate the effects of combination chemotherapy on HIV-1 surrogate markers in an HIV-1-infected patient with an advanced epithelial ovarian cancer. Cisplatin combined with cyclophosphamide was well-tolerated, without significant changes in the HIV-1 p24 antigen, neopterin, beta 2-microglobulin, and CD4 values. The patient demonstrated a chemical and clinical response to therapy, without evidence of opportunistic infection or severe neutropenia. During the 6-month period of observation, treatment with cisplatin and cyclophosphamide did not significantly increase the risk of HIV-1 disease progression.
Fishman
D A
DA
Division of Gynecologic Oncology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Viscarello
R R
RR
Cass
I
I
Schwartz
P E
PE
D000328:Adult; D015415:Biomarkers / Q000032:analysis; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D018284:Cystadenocarcinoma, Serous / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000601:surgery
D015415:Biomarkers; D003520:Cyclophosphamide; D002945:Cisplatin